| Status: Recommended | |||
Stiripentol (Diacomit®) is recommended for use within NHS Wales for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) whose seizures are not adequately controlled with clobazam and valproate. |
|||
|
|||
Medicine details |
|||
| Medicine name | stiripentol (Diacomit®) | ||
| Formulation | 250 mg, 500 mg powder for oral suspension; 250 mg, 500 mg hard capsule | ||
| Reference number | 3468 | ||
| Indication | In conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome) whose seizures are not adequately controlled with clobazam and valproate |
||
| Company | Biocodex | ||
| BNF chapter | Central nervous system | ||
| Submission type | Resubmission | ||
| Status | Recommended | ||
| Advice number | 2617 | ||
| NMG meeting date | 04/10/2017 | ||
| AWMSG meeting date | 08/11/2017 | ||
| Date of issue | 28/11/2017 | ||
| Date of last review | November 2020 | ||